Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01258348 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Trial in Patients With Renal Cell Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01258348 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 21 participants.
The verdict
NCT01258348, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to determine a safe dose of LY573636-sodium to be given in combination with sunitinib to patients with metastatic Renal Cell Carcinoma (RCC) and to determine any side effects that may be associated with LY573636-sodium and sunitinib combination in this patient population. The tumor response rate will also be assessed.
Interventions
- DRUG Sunitinib
- DRUG Drug: LY573636-sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01258348
The ClinicalTrials.gov registry entry for NCT01258348 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sunitinib is the first listed.
NCT01258348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01258348 about?
NCT01258348 is a clinical study titled "A Phase 1b Trial in Patients With Renal Cell Cancer". The purpose of this study is to determine a safe dose of LY573636-sodium to be given in combination with sunitinib to patients with metastatic Renal Cell Carcinoma (RCC) and to determine any side effects that may be associated with LY573636-sodium and sunitinib combination in this patient population...
What is the current status of trial NCT01258348?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2008-07. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01258348?
The interventions under investigation include: Sunitinib (DRUG), Drug: LY573636-sodium (DRUG).
Who is sponsoring clinical trial NCT01258348?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.